ON2 Cancer pathogenesis

Descripción

(Oncology) PHCY320 Test sobre ON2 Cancer pathogenesis, creado por Mer Scott el 05/10/2019.
Mer Scott
Test por Mer Scott, actualizado hace más de 1 año
Mer Scott
Creado por Mer Scott hace alrededor de 5 años
4
0

Resumen del Recurso

Pregunta 1

Pregunta
Oncogenesis is the mechanism by which a tumor arises, involving DNA [blank_start]mutation[blank_end]. If the DNA is not repaired, the cell will continue to [blank_start]divide[blank_end] and 'fix' the mutation in place. Successive mutations can build up until the cell division is no longer regulated.
Respuesta
  • mutation
  • divide

Pregunta 2

Pregunta
Oncogenesis: • 1 mutation is not enough, need [blank_start]multiple[blank_end] mutations • Number of mutations varies – impacts on [blank_start]immunogenicity & prognosis[blank_end] • These should generally be picked up at the [blank_start]check[blank_end] points, and the DNA repaired, unless the checkpoint itself is mutated (‘[blank_start]driver[blank_end]’ mutation)…
Respuesta
  • multiple
  • immunogenicity & prognosis
  • check
  • driver

Pregunta 3

Pregunta
Which of these is not an origin of mutations?
Respuesta
  • DNA replication
  • Inherited
  • Environmental insult
  • Infectious agents
  • GMOs

Pregunta 4

Pregunta
DNA replication • normal DNA replication introduces 1 mutation /10^7 nucleotides • most mutations still [blank_start]won’t[blank_end] cause cancer, however there are some [blank_start]key[blank_end] gene families in which a mutation can lead to oncogenesis: - tumor suppressor genes([blank_start]inactive[blank_end] in cancer): [blank_start]growth[blank_end] factors & growth regulators, repair & [blank_start]apoptosis[blank_end] genes, contact inhibition genes - activator genes (oncogenes & proto-oncogenes, [blank_start]active[blank_end] in cancer): angiogenic genes – eg [blank_start]vascular endothelial[blank_end] growth factor (VEGF), genes which allow metastasis and escape from [blank_start]immune[blank_end] surveillance
Respuesta
  • won’t
  • key
  • inactive
  • apoptosis
  • growth
  • active
  • vascular endothelial
  • immune

Pregunta 5

Pregunta
Inherited mutations • some forms of cancer have a higher occurrence in some families • they have inherited either: - defective [blank_start]tumor suppressor[blank_end] genes - activated [blank_start]oncogenes[blank_end] BRCA is a tumor [blank_start]suppressor[blank_end] gene involved in repairing DNA [blank_start]damage[blank_end]. BRCA1/2 mutation results is a 56–84% lifetime risk of developing [blank_start]breast[blank_end] cancer and an 36–63% risk for [blank_start]ovarian[blank_end] cancer.
Respuesta
  • tumor suppressor
  • oncogenes
  • suppressor
  • damage
  • breast
  • ovarian

Pregunta 6

Pregunta
Environmental Insult: • Chemical = carcinogens. Either [blank_start]directly[blank_end] damage DNA or their [blank_start]metabolites[blank_end] damage DNA. Types of damage are strand [blank_start]breakage[blank_end], gene [blank_start]truncation[blank_end], nucleotide deletions & substitutions. Most common chemically induced cancer - lung cancer ([blank_start]30[blank_end]% of all cancer deaths). • Physical = radiation – variable toxicity. Non-ionizing: • UV, microwaves. • UV causes [blank_start]melanoma[blank_end] Ionizing: • X-rays, g-rays, atomic bombs, nuclear reactors • [blank_start]Spontaneous[blank_end] tumor development (thyroid, breast, bone marrow)
Respuesta
  • directly
  • metabolites
  • breakage
  • truncation
  • 30
  • melanoma
  • Spontaneous

Pregunta 7

Pregunta
Human Papillomavirus Viruses (HPV) is an infectious agent that can cause cancer. HPV is isolated from > 90% of [blank_start]cervical[blank_end] tumors. HPV also causes [blank_start]anogenital and oropharnygeal[blank_end] carcinoma. High risk’ cancer-causing types: - HPV-[blank_start]16[blank_end] (55% of tumors) - HPV-18 (15%) - HPV-45 (10%)
Respuesta
  • cervical
  • anogenital and oropharnygeal
  • 16

Pregunta 8

Pregunta
The immune system has pro-tumor effects - chronic inflammation has been associated with oncogenesis, and anti-tumor effects - immune system can kill cancer cells.
Respuesta
  • True
  • False

Pregunta 9

Pregunta
CD8 T cells must be activated by a professional [blank_start]antigen presenting cell[blank_end] (APC) to kill cancerous cells. The problem is we need to get activation of the APC, but there is no infection. Hopefully there is enough [blank_start]necrosis[blank_end] and/or cell [blank_start]stress[blank_end] to activate the APC. The [blank_start]cytotoxic[blank_end] immune response should kill tumours but tumors are [blank_start]self[blank_end] tissues. CD8 T cells are not allowed to destroy cells expressing self [blank_start]antigens[blank_end]. The solution is an immune response directed against: [blank_start]mutated[blank_end] antigens (new proteins in genetically unstable cells), viral proteins, or [blank_start]inappropriately expressed[blank_end] antigens.
Respuesta
  • antigen presenting cell
  • necrosis
  • stress
  • cytotoxic
  • self
  • antigens
  • mutated
  • inappropriately expressed

Pregunta 10

Pregunta
Which of these is NOT an immune evasion strategy used by tumours?
Respuesta
  • not make any tumor antigens
  • shut down antigen presentation
  • shut down MHC class I expression
  • shut down expression of co-stimulator or adhesion molecules
  • not make immune cells

Pregunta 11

Pregunta
Tumor is immunosuppressive. • Tumour expresses [blank_start]T cell apoptosis[blank_end] molecules eg Fas L • Tumour secretes anti-inflammatory or suppressive molecules eg TGFb, [blank_start]IL-10, PGE-2[blank_end]
Respuesta
  • T cell apoptosis
  • IL-10, PGE-2
Mostrar resumen completo Ocultar resumen completo

Similar

Oncology Final MCQs 1- 5th Year PMU
Med Student
Test of Nuclear Medicine- Oncology 5th Year PMU
Med Student
Neurosurgery Module II - Neuro-oncology
Matthew Coulson
Cancer Genetics
Farrah
PATHO LE2: Neoplasia
Jessica Margaux Mercado
HPV Natural history
Nicole Neumann
Introduction to Oncology - Drugs
Ryan Kidd
Approach to childhood malignany
Averil Tam
Oncology
James Sante
Hematology
annerao
Oncology Quiz #1
Mostapha Abdelkader